|Bid||0.00 x 47300|
|Ask||3.30 x 900|
|Day's Range||2.90 - 3.05|
|52 Week Range||1.55 - 5.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.25|
REDWOOD CITY, Calif., Aug. 8, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx's common stock. Including this option exercise, total gross proceeds to AcelRx from the offering of an aggregate 8,363,636 shares at a price to the public of $2.75 per share were approximately $23.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by AcelRx. Ladenburg Thalmann acted as co-manager for the offering.
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.26% and -11.57%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 20 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- European Commission approved DZUVEO (sufentanil sublingual tablet, 30 mcg) for the management of acute moderate-to-severe pain in adults in medically monitored settings - June 30, 2018 cash and short-term ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...
CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results ...
On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), and MiMedx Group Inc. (NASDAQ: MDXG).
Not everyone is excited about AcelRx Pharmaceuticals (NASDAQ:ACRX), which focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. Despite the potential advantages, Oppenheimer analyst Leland Gershell believes the drug maker's products may face challenges with market penetration given: (1) the broad effort to reduce opioids' dominant role in analgesia, (2) the unclear advantage of needle-free delivery in populations who typically get IV access, and (3) the lack of physician familiarity with their active ingredient. Anesthesiologists and other specialists we have spoken with agree that Dsuvia could find some utility for acute pain management, and highlight the palliative care setting (e.g. AcelRx's acute pain drug Dsuvia has a November 3, 2018 FDA action date, in advance of which management expects the agency to hold an Advisory Committee meeting.
REDWOOD CITY, Calif., July 12, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced the pricing of its previously announced underwritten public offering of 7,272,727 shares of its common stock, at a public offering price of $2.75 per share. The gross proceeds to AcelRx from this offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by AcelRx, are expected to be approximately $20 million. All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about July 16, 2018, subject to the satisfaction of customary closing conditions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
REDWOOD CITY, Calif., July 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced that it has commenced an underwritten public offering of shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the proposed offering will be sold by AcelRx. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering.
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.
FDA regulators rejected its drug-device in October, sending its stock sharply lower. Now this company believes new data, Defense Department and hospital shortages of painkillers could help it score approval in November like it did in Europe last month.
REDWOOD CITY, Calif., June 27, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the European Commission (EC) has approved DZUVEO (under development in the U.S. as DSUVIA™) for the management of acute moderate to severe pain in adults in medically monitored settings.
Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.
This Monday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), Accuray Inc. (NASDAQ: ARAY), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). All you have to do is sign up today for this free limited time offer by clicking the link below.
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has been slowly recovering from a mid-October plunge following the FDA's issuance of a Complete Response Letter. “Since ACRX obtained a CRL in 2017, the company has addressed the FDA's concerns, and reduced the maximum daily dosage of Dsuvia to 12 doses from 24,” the analyst said.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southern ...